Bicycle Therapeutics Income Before Tax Over Time
| BCYC Stock | USD 20.40 0.05 0.25% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Bicycle Therapeutics Performance and Bicycle Therapeutics Correlation. Bicycle |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bicycle Therapeutics. If investors know Bicycle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bicycle Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.28) | Revenue Per Share 0.716 | Quarterly Revenue Growth (0.50) | Return On Assets (0.15) | Return On Equity (0.27) |
The market value of Bicycle Therapeutics is measured differently than its book value, which is the value of Bicycle that is recorded on the company's balance sheet. Investors also form their own opinion of Bicycle Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Bicycle Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bicycle Therapeutics' market value can be influenced by many factors that don't directly affect Bicycle Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bicycle Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bicycle Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bicycle Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Income Before Tax Analysis
Compare Bicycle Therapeutics and related stocks such as Ideaya Biosciences, AnaptysBio, and MeiraGTx Holdings PLC Income Before Tax Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IDYA | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (34.3 M) | (42 M) | (34.5 M) | (49.8 M) | (58.7 M) | (113 M) | (107.3 M) |
| ANAB | (5.5 M) | (5.5 M) | (5.5 M) | (5.5 M) | 3.5 M | (5.3 M) | (4.3 M) | (30.1 M) | (61.8 M) | (97.5 M) | (19.9 M) | (57.8 M) | (128.7 M) | (163.6 M) | (155.4 M) |
| MGTX | (19.8 M) | (19.8 M) | (19.8 M) | (19.8 M) | (19.8 M) | (19.8 M) | (19.8 M) | (31 M) | (83.3 M) | (54.7 M) | (58 M) | (79.6 M) | (129.6 M) | (84 M) | (88.2 M) |
| KROS | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (12.3 M) | (45.5 M) | (56.7 M) | (104.7 M) | (153 M) | (145.3 M) |
| TNYA | (26.2 M) | (26.2 M) | (26.2 M) | (26.2 M) | (26.2 M) | (26.2 M) | (26.2 M) | (26.2 M) | (26.2 M) | (26.2 M) | (38.4 M) | (72.7 M) | (123.7 M) | (124.1 M) | (117.9 M) |
| IGMS | (11.1 M) | (11.1 M) | (11.1 M) | (11.1 M) | (11.1 M) | (11.1 M) | (11.1 M) | (11.1 M) | (22.7 M) | (43.1 M) | (81.4 M) | (165.2 M) | (221.1 M) | (245.7 M) | (233.5 M) |
| GLUE | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (35.9 M) | (74 M) | (108.5 M) | (135 M) | (128.3 M) |
| STOK | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (12.5 M) | (32.3 M) | (52.2 M) | (85.8 M) | (101.1 M) | (104.7 M) | (99.5 M) |
| MRUS | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (21.2 M) | (25.3 M) | (49.7 M) | (87.4 M) | (27.4 M) | (55 M) | (85 M) | (66.6 M) | (130.2 M) | (151.7 M) | (144.2 M) |
| INBX | (21.8 M) | (21.8 M) | (21.8 M) | (21.8 M) | (21.8 M) | (21.8 M) | (21.8 M) | (21.8 M) | (30.9 M) | (50.5 M) | (75.6 M) | (81.8 M) | (145.2 M) | (239.7 M) | (227.7 M) |
| IMTXW | (32.4 M) | (32.4 M) | (32.4 M) | (32.4 M) | (32.4 M) | (32.4 M) | (32.4 M) | (32.4 M) | (32.4 M) | (32.5 M) | (229.6 M) | (93.3 M) | 42 M | (97 M) | (101.8 M) |
| SEER | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (16 M) | (32.8 M) | (71.2 M) | (93 M) | (86.3 M) | (82 M) |
| ORIC | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (26.9 M) | (73.7 M) | (78.7 M) | (89.1 M) | (100.7 M) | (105.7 M) |
| ANEB | (174.6 K) | (174.6 K) | (174.6 K) | (174.6 K) | (174.6 K) | (174.6 K) | (174.6 K) | (174.6 K) | (174.6 K) | (174.6 K) | (30.3 M) | (6.8 M) | (11.7 M) | (8.2 M) | (8.6 M) |
| CGEM | (704.7 K) | (704.7 K) | (704.7 K) | (704.7 K) | (130.5 K) | (109.5 K) | (316.7 K) | (14.2 M) | (14.2 M) | (21.7 M) | (59.5 M) | (67.5 M) | 151.3 M | (169.2 M) | (160.8 M) |
| CCCC | (15.7 M) | (15.7 M) | (15.7 M) | (15.7 M) | (15.7 M) | (15.7 M) | (15.7 M) | (15.7 M) | (15.7 M) | (33.3 M) | (67 M) | (83.9 M) | (128.2 M) | (131.2 M) | (124.7 M) |
| ADAG | (15.3 M) | (15.3 M) | (15.3 M) | (15.3 M) | (15.3 M) | (15.3 M) | (15.3 M) | (15.3 M) | (15.3 M) | (16.4 M) | (16.4 M) | (71.5 M) | (79.5 M) | (17.3 M) | (18.1 M) |
| ACRV | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (16.2 M) | (31.2 M) | (60.4 M) | (57.4 M) |
| MLYS | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (19.4 M) | (29.8 M) | (71.9 M) | (68.3 M) |
Bicycle Therapeutics and related stocks such as Ideaya Biosciences, AnaptysBio, and MeiraGTx Holdings PLC Income Before Tax description
Income Before Tax which can also be referred as pre-tax income is reported on Bicycle Therapeutics income statement and is an important metric when analyzing Bicycle Therapeutics profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.My Equities
My Current Equities and Potential Positions
| Bicycle Therapeutics | BCYC |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | United Kingdom |
| Exchange | NASDAQ Exchange |
USD 20.4
Check out Bicycle Therapeutics Performance and Bicycle Therapeutics Correlation. For information on how to trade Bicycle Stock refer to our How to Trade Bicycle Stock guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Bicycle Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.